- Home
- BARK vs COEP Comparison
BARK vs COEP Comparison
Compare BARK & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BARK | COEP |
|---|---|---|
| Founded | 2011 | 2017 |
| Country | United States | United States |
| Employees | N/A | 7 |
| Industry | Department/Specialty Retail Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 92.7M | 72.7M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | BARK | COEP |
|---|---|---|
| Price | $0.81 | $12.10 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $2.50 | N/A |
| AVG Volume (30 Days) | ★ 729.3K | 32.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.43 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.53 | $6.32 |
| 52 Week High | $1.48 | $21.41 |
Technical Indicators
Market Signals| Indicator | BARK | COEP |
|---|---|---|
| Relative Strength Index (RSI) | 54.30 | 45.22 |
| Support Level | $0.80 | $11.76 |
| Resistance Level | $0.86 | $13.23 |
| Average True Range (ATR) | 0.04 | 0.86 |
| MACD | 0.00 | 0.11 |
| Stochastic Oscillator | 60.77 | 34.13 |
Price Performance
Historical ComparisonAbout BARK BARK Inc.
BARK Inc is a vertically integrated, omnichannel brand serving dogs across two key categories: toys & accessories and consumables. It serves dogs nationwide with monthly subscription services, BarkBox and Super Chewer; e-commerce experience on BarkShop.com; custom collections via its retail partner network, including Target and Amazon; wellness products that meet dogs' needs with BARK Bright; and a personalized meal delivery service for dogs BARK Eats. The company's reportable segments are; Direct to Consumer (D2C), and Commerce. The majority of its revenue is generated from the Direct to Consumer segment which derives revenue from the sale of toys & accessories and consumables through BarkBox, Super Chewer, and the company's consumables website.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.